Supernus Pharmaceuticals (SUPN) Receives News Sentiment Score of 0.10
Media stories about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.4113697979219 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Supernus Pharmaceuticals (NASDAQ SUPN) traded up $0.55 during trading hours on Friday, reaching $42.05. 347,083 shares of the company traded hands, compared to its average volume of 361,063. The company has a current ratio of 1.94, a quick ratio of 1.74 and a debt-to-equity ratio of 0.01. Supernus Pharmaceuticals has a twelve month low of $17.25 and a twelve month high of $50.04. The firm has a market cap of $2,131.89, a P/E ratio of 36.89, a PEG ratio of 1.84 and a beta of 1.30.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. equities analysts predict that Supernus Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday. Piper Jaffray Companies set a $41.00 price target on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, October 29th. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $49.78.
In related news, VP Padmanabh P. Bhatt sold 3,709 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now directly owns 17,500 shares in the company, valued at approximately $791,525. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stefan K.F. Schwabe sold 95,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by corporate insiders.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.